Core Insights - Eli Lilly is set to produce its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing facility in Texas [1] Company Developments - The new manufacturing plant will be dedicated to the production of orforglipron, indicating a significant investment in expanding the company's capabilities in the weight-loss medication market [1]

Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. Eli Lilly ...

Accessibility StatementSkip Navigation The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS, Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine a ...

Core Insights - The competition in the weight loss drug market is intensifying, particularly between Eli Lilly and Novo Nordisk, with both companies releasing significant clinical trial data for their GLP-1 receptor agonists [1][2][3] Group 1: Clinical Trial Results - Eli Lilly's Orforglipron showed an average weight loss of 12.4 kg (12.4%) in the highest dose group after 72 weeks [1] - Novo Nordisk's oral semaglutide (25 mg) demonstrated a 16.6% average weight loss after 64 weeks in a study involving 307 patients, compared to 2.7% in the placebo group [2][3] - In the same study, over one-third (34.4%) of patients on oral semaglutide achieved a weight loss of 20% or more, while only 2.9% in the placebo group reached this threshold [2] Group 2: Regulatory and Market Developments - Novo Nordisk plans to submit a new drug application for oral semaglutide to the FDA by the end of the year, with production facilities already expanded [3] - Eli Lilly anticipates submitting a global regulatory application for Orforglipron by the end of 2025 [4] Group 3: Market Dynamics and Acquisitions - The market for weight loss drugs is seeing a narrowing of business development expectations as more products enter the market [5] - Pfizer announced a $7.3 billion acquisition of Metsera, a company focused on weight loss drug development, indicating a shift in MNCs' acquisition strategies towards companies with innovative technology platforms [6]

Core Points - Boys & Girls Clubs of America received a $10 million grant from Lilly Endowment Inc. to support over 250 Clubs on or near Native lands, aiming to enhance access to high-quality programs for youth in these communities [1][2] - The grant will be utilized over three years to expand the capacity of the Clubs, focusing on leadership development, digital transformation, and program quality [1][7] - Boys & Girls Clubs of America serves more than 4 million youth annually, including 120,000 from Native communities, and has a long-standing commitment to supporting these communities [2][4] Funding and Support - The funding from Lilly Endowment Inc. will allow Boys & Girls Clubs to deepen their commitment to youth and Native communities through innovative and sustainable solutions [3] - Lilly Endowment has supported Boys & Girls Clubs for over 70 years, emphasizing the importance of character building and healthy relationships for youth success [3][6] Program Expansion - The grant will enable Boys & Girls Clubs to strengthen program quality in areas such as academics, mental health, and community engagement [7] - Investment in leadership development will provide training and resources for Club leaders and youth, enhancing long-term community capacity [7] - The initiative will also focus on advancing digital transformation to modernize technology infrastructure, particularly in rural and Native communities [7]

Group 1 - Celltrion Inc. announced that its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly for $330 million [1]

Core Insights - Innovent Biologics has launched a new weight-loss drug that is gaining traction in the Chinese market, intensifying competition with Western counterparts [1] - The company's marketing strategy is proving effective, leading to increased market penetration and consumer interest [1] Company Summary - Innovent Biologics is focusing on the weight-loss drug segment, which is becoming increasingly competitive in China [1] - The company aims to leverage its marketing strategy to differentiate itself from Western competitors [1] Industry Summary - The weight-loss drug market in China is experiencing growth, with local companies like Innovent Biologics challenging established Western firms [1] - The competitive landscape is shifting as domestic players enhance their marketing efforts and product offerings [1]

Let's talk with Scott Zary, healthc care director, S&P global ratings. I'll start with is the demand growing, slowing, or about the same for all of these drugs that they are obesity drugs, but people are using them just to look lose weight and feel better. Um, tell me about the demand cycle.Uh, thank you for having me on. I I think every time I look at the forecast for this company, the demand uh for Lily, that is the demand continues to grow for uh GLP1s across the board. So I think um when you look at it, ...

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. The second quarter of 2025 endured significant government policy changes and geopolitical events, which resulted in volatility yet ended with robust performance for equity markets. The Fund’s Institutional Class shares posted an absolute positive return of 11.24% in the quarter, but underperformed the benchma ...

Key Points Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain attractive, especially while the stock is still down year to date. 10 stocks we like better than Eli Lilly › It's been a volatile year for Eli Lilly (NYSE: LLY), with the pharmaceutical giant experiencing some setbacks. However, the drugmaker has been on a roll over the past month, with several ...